Robert J Ulrich, Andrea B Troxel, Ellie Carmody, Jaishvi Eapen, Martin Bäcker, Jack A DeHovitz, Prithiv J Prasad, Yi Li, Camila Delgado, Morris Jrada, Gabriel A Robbins, Brooklyn Henderson, Alexander Hrycko, Dinuli Delpachitra, Vanessa Raabe, Jonathan S Austrian, Yanina Dubrovskaya, Mark J Mulligan
Background: Effective therapies to combat coronavirus 2019 (COVID-19) are urgently needed. Hydroxychloroquine (HCQ) has in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the clinical benefit of HCQ in treating COVID-19 is unclear. Randomized controlled trials are needed to determine the safety and efficacy of HCQ for the treatment of hospitalized patients with COVID-19. Methods: We conducted a multicenter, double-blind randomized clinical trial of HCQ among patients hospitalized with laboratory-confirmed COVID-19...
October 2020: Open Forum Infectious Diseases